CD38 and neoplasm: Daratumumab, an IgGκ humanized monoclonal antibody, specifically binds to CD38.[37] It induces cell apoptosis through Fc-mediated crosslinking and exerts immunomodulatory effects, such as antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cellular phagocytosis.[38,39] These mechanisms contribute to tumor cell lysis and the inhibition of CD38-expressing tumor cell growth.